UNSPSC 51392003: Cinamolol

This classification denotes a beta-adrenergic blocking agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7531Q8398Y. European Medicines Agency schedules Cinamolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06284MIG. Cinamolol generally arises in the molecular formula C16H23NO4.

UNSPSC 51392003 Cinamolol is a Commodity code that in recent state and local procurement activity captures acquisition of pharmaceutical products and related health-system supplies, though the code's nominal scope and actual solicitation content show significant misalignment. The recent opportunities tagged under this code involve naloxone procurement and direct-to-manufacturer prescription program planning rather than cinamolol (a beta-blocker cardiovascular medication) specifically. Issuing bodies soliciting under this code include county health departments and state health and human services agencies pursuing pharmacy and emergency-response supply chains. Seminole County, Florida and the Texas Health and Human Services Commission are the two recent buyers on record.

Geographic activity centers on Florida and Texas. Seminole County's IFB 60459723LAS, posted June 30, 2026, seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, response due July 26, 2023 (note: the due date appears misrecorded in the source). The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program that would establish direct contracting between state pharmacy benefit programs and pharmaceutical manufacturers outside traditional pharmacy benefit manager and wholesaler channels. The RFI is exploratory and does not commit to specific contract values or timelines; responses inform future RFP development. Both opportunities require vendor compliance with E-Verify and standard liability insurance, and neither specifies set-asides for disadvantaged enterprises.